Although mammalian MBD3 contains the mCpG-binding domain (MBD) and is highly homologous with the authentic mCpG-binding protein MBD2, it was reported that the protein does not bind to mCpG specifically. Using recombinant human wild type and mutant MBD3 proteins, we demonstrated that atypical amino acids found in MBD3 MBD, namely, His-30 and Phe-34, are responsible for the inability of MBD3 to bind to mCpG. Interestingly, although H30K/F34Y MBD3 mutant protein binds to mCpG efficiently in vitro, it was not localized at the mCpG-rich pericentromeric regions in mouse cells. We also showed that Y34F MBD2b MBD, which possesses not the mCpG-specific DNA-binding activity but the nonspecific DNA-binding activity, was localized at the pericentromeric regions. These results suggested that the mCpG-specific DNA-binding activity is largely dispensable, and another factor(s) is required for the localization of MBD proteins in vivo. MBD3 was identified as a component of the NuRD/Mi2 complex that shows chromatin remodeling and histone deacetylase activities. We demonstrated that MBD3 MBD is necessary and sufficient for binding to HDAC1 and MTA2, two components of the NuRD/Mi2 complex. It was therefore suggested that mCpG-binding-defective MBD3 has evolutionarily conserved its MBD because of the secondary role played by the MBD in protein-protein interactions.
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and MeCP2, have been identified in mammals and are collectively called MBD family proteins because these proteins share the mCpG-binding domain (1, 2) . MBD4 recognizes the T/G mismatched base pair, and is a component of the DNA repair machinery (3, 4) . MBD1, MBD2, and MeCP2 have been well characterized for their gene-repressing activities. These proteins bind to mCpG via MBD and recruit histone deacetylase (HDAC) complexes to the binding sites via their separate domain called TRD (transcriptional repression domain). The deacetylation by HDAC of the core histones H3 and H4 is partly responsible for the gene repression mediated by these MBD proteins (1, (5) (6) (7) . In contrast to these well characterized MBD proteins, the function of MBD3 remains unclear. Although MBD2 and MBD3 are highly homologous in and outside MBD, experiments performed in vitro and in vivo failed to demonstrate the mCpG-binding activity of recombinant mouse MBD3 (2) . A controversy arose when Xenopus MBD3 was isolated and demonstrated to possess mCpG-binding activity (8) . However, recent studies have pointed out that amino acids in MBDs critical for binding to mCpG are present in Xenopus MBD3 but not in mammalian MBD3. These amino acid substitutions are likely responsible for the inability of mammalian MBD3 to bind to mCpG (9, 10) .
Recently, it was reported that the NuRD/Mi2 complex contains MBD3 as a component (8, 11) . The complex consists of Rpd3-like histone deacetylase, RbAp46/p48, MTA2, CHD4/ Mi2beta, and MBD3 and possesses DNA-dependent ATPase, chromatin remodeling activity, and histone deacetylase activity (12) . Thus, it has been proposed that the NuRD/Mi2 complex plays a role in gene repression through histone deacetylation and chromatin packaging in methyl-CpG-rich regions (13) . However, the role of MBD3 in the NuRD/Mi2 complex is again controversial. In one study, it was shown that the human NuRD/Mi2 complex does not bind to mCpG, but is recruited to mCpG by interacting with the authentic mCpG-binding protein MBD2 (11, 14) . In another study, the Xenopus NuRD/Mi2 complex and its component xMBD3 were shown to have specific mCpG-binding activity on their own (8) .
In this study, we aimed at clarifying the mCpG-binding activity of human MBD3. Specifically, we constructed mutant MBD3 proteins in which atypical amino acids occupying the critical residues in other MBD proteins were "corrected" to the conserved amino acids. We found that such MBD3 mutants indeed showed specific binding activity to mCpG in vitro as proposed previously. However, unexpectedly, such mutants did not associate with murine pericentromeric regions that are highly rich in mCpG. These results suggest that other factors are necessary for the targeting of MBD proteins in vivo in addition to the mCpG-binding activity.
MATERIALS AND METHODS
Plasmids-Mutant MBD3 cDNAs having point mutations were generated by the site-directed mutagenesis kit (TaKaRa). Other truncated cDNAs were generated by PCR. All cDNAs were confirmed for nucleotide sequences. Recombinant proteins were expressed in Escherichia coli using pGEX5x-1 (Amersham Biosciences) or pET32c (Novagen) vectors. For the analysis of subcellular localization, cDNAs encoding MBD2b and MBD3 tagged with the HA epitope at their N termini were subcloned in pcDNA3 (Invitrogen), transfected, and expressed in NIH 3T3 cells.
Recombinant Proteins-GST-fused recombinant proteins were expressed in E. coli XLIblue MRFЈ (Stratagene) and purified using glutathione-Sepharose CL-4B beads (Amersham Biosciences). His-tagged MTA2 and HDAC1 proteins were expressed in E. coli BL21(DE3). The cells were lysed by sonication in buffer containing 500 mM NaCl, 10 mM Tris-Cl (pH 8.5), 0.5% Triton X-100, and 10 mM 2-mercaptoethanol supplemented with the complete protease inhibitor tablet (Roche). After centrifugation, the supernatant was found not to contain soluble recombinant proteins. The pellet was dissolved in 8 M urea, 50 mM Tris-Cl (pH 8.5), and 0.5% Triton X-100. These solutions were dialyzed against 500 mM NaCl, 10 mM Tris-Cl (pH 8.5), 0.05% Triton X-100, 10% glycerol, and 10 mM 2-mercaptoethanol. After removing insoluble materials by ultracentrifugation, partially purified MTA2 or HDAC1 was obtained.
GST Pull-Down Assay-GST-fused MBD3 proteins were incubated with glutathione-Sepharose CL-4B beads for 60 min in PBS. After washing the beads twice with PBS to remove unbound GST-fused proteins, the beads were incubated with target proteins suspended in the binding buffer (PBS with 0.05% Nonidet P-40, 1 mM dithiothreitol, and protease inhibitor mixture (Complete, Roche)). The binding buffer for HDAC1 contained 0.3 M NaCl. After washing the beads three times with the binding buffer, the protein bound to the beads was detected by SDS-PAGE and immunoblotting.
Electrophoretic Mobility Shift Assay (EMSA)-EMSA was performed essentially as previously described (15) , except that the buffer contained 20 ng of sonicated E. coli genomic DNA in 20 l of binding reaction mixture. The double-stranded DNA oligonucleotides used as the probe was: 5Ј-GCCTTCAGACCCGGAGATCCAG-3Ј (upper strand) and 5Ј-ACTGGGATCTCCCGGTCTGAAGG-3Ј (lower strand). The two underlined cytosines were unmethylated in the unmethylated probe (U) and both methylated in the methylated probe (M). Approximately 100 ng of recombinant proteins was added to 20 l of the reaction mixture containing the probes. Protein-DNA complexes were fractionated in 4% polyacrylamide gel supplemented with 3% glycerol in 0.5ϫ TBE at 4°C. The gel was analyzed using a phosphoimager (Fuji, BAS-2000) .
Indirect Immunofluorescence-After washing with PBS, cells were permeabilized with 0.5% Triton X-100 in PBS for 2 min at room temperature. Cells were washed with PBS twice and fixed with 4% paraformaldehyde in PBS for 10 min at room temperature. Cells were treated twice with TBS containing 0.2% Tween 20 followed by incubation with anti-HA antibodies for 60 min at room temperature. Cells were then incubated with Alexa488-conjugated anti-mouse Ig antibodies (Molecular Probes) for 60 min at room temperature and mounted on slides with the mounting medium containing DAPI (Vectashield, Vector Laboratories). The samples were examined under a fluorescence microscope (Zeiss).
DNA-binding Assay-The purified GST-fused recombinant proteins and 0.1 pmol of labeled oligonucleotides were incubated in 100 l of PBS with glutathione-Sepharose CL-4B beads for 30 min. After a brief centrifugation to sediment the beads, the supernatant was collected for scintillation counting. After washing three times with PBS to remove unbound oligonucleotides, the beads were suspended in PBS. The slurry and the supernatant were transferred to Ready Cap (Beckman) and subjected to scintillation counting. DNA-binding efficiency was calculated as Efficiency ϭ Ppt/(SupϩPpt), where Sup is the count of the first supernatant and Ppt is that of the slurry (beads).
RESULTS

His-30 and Phe-34 Are Responsible for the Inability of MBD3
to Bind to mCpG-An NMR study revealed that five amino acid residues in the MBD domain of human MBD1 play important roles in recognizing the methyl groups of mCpG/mCpG (16) . These amino acid residues, Val-20, Arg-22, Tyr-34, Arg-44, and Ser-45, are highly conserved in MBD family members. Interestingly, these residues are also conserved in xMBD3 but not in human and mouse MBD3s where Tyr-34 is replaced with Phe-34 (the numbering of equivalent amino acids in MBD1 and MBD3 is the same). In addition, the same study showed that Arg-30 of MBD1 MBD interacts with the DNA backbone. Basic amino acids are present at this position in most MBD proteins including xMBD3. However, mammalian MBD3s contain an atypical residue, His, at this position. Therefore, it was hypothesized that these two amino acid substitutions specific to mammalian MBD3 might be responsible for the reported inability of the protein to bind to mCpG (9, 16) . To test this hypothesis, we prepared three human MBD3 mutants (Fig. 1A) . MBD3-H30K and MBD3-F34Y encode mutant MBD3s in which His-30 and Phe-34 are replaced with Lys and Tyr, respectively. MBD3-H30K/F34Y encodes mutant MBD3 having both substitutions. These mutants were designed to correct the MBD3-specific atypical residues to conserved ones.
The N-terminal 92 amino acids of wild type and mutant MBD3s were expressed in E. coli as N-terminally GST-fused proteins. These fusion proteins contain the entire MBD3 MBD that comprises the N-terminal 75 amino acids. The recombinant proteins were purified using glutathione-Sepharose CL-4B beads (Fig. 1B) , and subjected to EMSA (Fig. 1C) . A 23-bp oligonucleotide containing a single CpG site at the center was used as a probe for EMSA. Two versions of oligonucleotides, U and M, were used. The single CpG/CpG is methylated not in U but in both strands in M. The GST-fused N-terminal wild type MBD3 (GST-wt(N)) produced a shifted band upon incubation with the labeled M probe. However, this shifted band was competed at similar efficiencies by a 100-fold excess of either unlabeled M or U. Thus, it was concluded that GSTwt(N) binds to DNA in a methylation-independent manner, as reported previously (2) . The GST-fused N-terminal MBD3-H30K (GST-H30K(N)) behaved in a manner similar to GSTwt(N). In contrast, the GST-fused N-terminal MBD-F34Y (GST-F34Y(N)) produced a shifted band upon incubation with the labeled M probe, and significantly, this band was competed more efficiently by 100-fold excess of unlabeled M than by unlabeled U. Therefore, it was suggested that substituting Tyr for Phe at residue 34 of MBD3 significantly increased the mCpG-specific DNA-binding activity. The GST-fused N-terminal MBD-H30K/F34Y (GST-H30K/F34Y(N)) showed essentially similar DNA-binding activities to those of GST-F34Y(N).
Because the above experiments did not give a quantitative idea of the DNA-binding activities of mutant proteins, we quantitatively measured the DNA-binding efficiency of those proteins. Different amounts of purified GST-MBD fusion proteins were incubated with 1 nM of labeled U or M oligonucleotides in the absence of any cold DNA. The fusion proteins were precipitated with glutathione-Sepharose CL-4B beads, and both pellet fractions and supernatant fractions were scintillationcounted for the labeled probes. The bound fraction of the DNA probe was determined from the following equation: Bound Fraction ϭ Ppt/(Supϩ Ppt), where Ppt and Sup represent the scintillation counts of Ppt and Sup, respectively. The values obtained in this way are plotted against the protein concentration (Fig. 2) . Both GST-wt(N) and GST-H30K(N) did not show significant binding to either U or M in this assay (Fig. 2, A and  B) . In contrast, GST-F34Y(N) showed weak but significant binding to the M probe (Fig. 2C) . It was not possible to deduce the K d value for this binding, however, because protein-DNAbinding was not saturated in the range of protein concentrations examined. Interestingly, GST-H30K/F34Y(N) showed a remarkable increase both in the binding affinity to DNA and in the specificity to bind to M rather than to U. K d between GST-H30K/F34Y(N) and M was estimated to be 9.32 ϫ 10 Ϫ8 M (Fig. 2D) . In a similar experiment, K d between M and the GST-fused MBD domain of MBD2b (amino acids 1-88, the region equivalent to the MBD3 MBD used in this study), a well characterized methyl-DNA-binding protein (17) , was estimated to be 2.67 ϫ 10 Ϫ8 M (Fig. 2E) . Therefore, simultaneous substitutions of H30K and F34Y conferred to MBD3 a methyl-DNAspecific binding activity that was comparable with that of MBD2b. These results supported the previous hypothesis that the two atypical amino acids at residues 30 and 34 are responsible for the inability of MBD3 to bind to mCpG specifically.
It was reported that Tyr-34 in MBD1 plays important roles both directly and indirectly in MBD1-mCpG binding (16) . Given the positive roles of this residue, it was expected that the substitution of Ala instead of Tyr for Phe-34 would not improve the DNA-binding activity of MBD3. Unexpectedly, however, GST-fused F34A(N) showed significantly higher DNA-binding activity than GST-wt(N) (Fig. 3, A and B) . Interestingly, GST-F34A(N) did not show any specificity to U or M, suggesting that Tyr-34 may be important for the mCpG-specific binding activity. The equivalent mutant of MBD2b, GST-MBD2b Y34A(N), also showed DNA-binding activity comparable with that of GST-F34A(N) (Fig. 3, A and C) . Similar observations have been previously reported for MeCP2. MeCP2 that had mutations at Tyr-123, the equivalent residue of Tyr-34 in MBD1, showed a reduced but significant binding activity to mCpG (18) . The simplest interpretation of these results is that Phe-34 in MBD3 has an inhibitory effect on nonspecific DNA-binding activity, and substituting any amino acid for this residue may lead to the recovery of the nonspecific DNA-binding activity.
Neither Wild Type nor Mutant MBD3 MBD Associates with mCpG-Rich Heterochromatin in Vivo-Questions regarding the ability of MBD3 to bind with mCpG in vivo were raised in an experiment in which MBD3-GFP proteins were expressed in mouse cells (2) . In mouse cells, ϳ50% of total mCpG is concentrated at pericentromeric regions that consist of the major satellite DNA. Pericentromeric regions are easily detected in interphase cells by virtue of their being brightly stained by DAPI. In a previous study (2, 22) , it was found that overexpressed mouse MBD1, MBD2, MBD4, and rat MeCP2 were localized at pericentromeric regions, supporting the proficient mCpG-binding activity of these proteins in vivo. In contrast, the overexpressed MBD3 protein was not localized at pericentromeric regions and instead was homogeneously distributed in the nuclei when MBD3 was expressed at a low level or accumulated as nuclear foci when it was expressed at a high level. Together with the data that human MBD3 does not bind to mCpG in vitro, it was concluded that MBD3 does not function as an mCpG-binding protein in vivo (2). Because we have found that the H30K/F34Y MBD3 mutant binds to mCpG efficiently in vitro, we were interested in examining whether or not this mutant protein associated with mCpG in vivo.
The MBD domains of wild type and mutant human MBD3s, as well as MBD2b, were overexpressed in mouse NIH 3T3 cells as HA-tagged proteins by transient DNA transfection. The cells were stained with DAPI for pericentromeric regions and with anti-HA antibodies for MBD localization (Fig. 4) . MBD2b MBD was localized at the pericentromeric regions (Fig. 4, c) , whereas wild type MBD3-derived MBD were distributed diffusely in the nuclei, as expected (Fig. 4, a) . Neither H30K, F34Y (data not shown), nor H30K/F34Y mutant MBD3 MBD (Fig. 4, b) colocalized at the pericentromeric regions. Because MBD3 H30K/ F34Y specifically binds to mCpG in vitro (Fig. 2E) , these results suggested that the ability of MBD proteins to associate with mCpG in vivo is not a simple reflection of the ability of these proteins to bind to mCpG in vitro.
Next, we performed similar analyses for the mutated versions of MBD2b. MBD2b MBD carrying the two substitutions found in wild type MBD3 (MBD2b K30H/Y34F(N)) was not co-localized at the pericentromeric regions, as expected (Fig. 4,  e) . Unexpectedly, MBD2b Y34F, which binds to DNA in an mCpG-independent manner (Fig. 3D) , was co-localized at the pericentromeric regions (Fig. 4, d) . Because MBD2b Y34F and MBD2b K30H/Y34F showed similar binding behaviors (i.e. mCpG-independent DNA-binding activity) (Fig. 3, D and E) , the different localizations of these two versions of MBD2b MBD in vivo again suggest the presence of other factors that determine the localization of MBD proteins in vivo in addition to the binding ability of the protein to DNA measured in vitro.
MBD3 Does Not Bind to Either the mCpG/TpG Mismatch or Methyl-cytosine in the CpA
Context-MBD4 specifically recognizes the mCpG/TpG mismatch sequence (3, 4) . Because we found that MBD3 MBD did not bind to mCpG/mCpG specifically, we next examined the possibility that MBD3 binds to the mCpG/TpG mismatch sequences using the assay system described in Fig. 2 . GST-fused recombinant protein of MBD4 MBD binds to an oligonucleotide containing CpG/TpG and at a higher affinity to one containing mCpG/TpG, as expected (Fig.  5A) . Under the same conditions, GST-fused MBD3 MBD did not bind to either CpG/TpG or mCpG/TpG.
Recently, it was reported that a minor population of meth- ylcytosine in the genome of mouse embryonic cells is present as CpA-dinucleotides (19) . We also tested the possibility that MBD3 MBD might bind specifically to this sequence. The recombinant MBD3 MBD protein did not show appreciable binding ability to either an mCpA/TpG-or a CpA/TpG-containing oligonucleotide (Fig. 5B) . These results indicate that MBD3 does not recognize these relatively minor populations of methylcytosine in the genome.
MBD Is Necessary and Sufficient for Binding to MTA2 and HDAC1-MBD3
was identified as a component of the NuRD/ Mi2 complex (8, 11) . In vitro, it was shown that human MBD3 directly binds to many NuRD/Mi2 components, including MTA2, HDAC1, RbAp46, and RbAp48. We examined regions in MBD3 responsible for binding to MTA2 and HDAC1. MBD3 (also called MBD3a) (11) and its deletion mutants were expressed as GST-fusion proteins in E. coli (Fig. 6A) . MBD3 proteins were incubated with recombinant full-length MTA2 or HDAC1 and sedimented with glutathione-Sepharose CL-4B beads. After washing the beads, MBD3 and associated proteins were examined by SDS-PAGE. All MBD3 proteins were confirmed for their expression and absorption by glutathioneSepharose CL-4B beads (Fig. 6, B and C) . Both MTA2 and HDAC1 were associated with all versions of MBD3 except one that lacks the N-terminal 92 amino acids that contain MBD (⌬N92). Reciprocally, the MBD3 mutant consisting of MBD only (⌬C93) associated with MTA2 and HDAC1. Therefore, MBD is necessary and sufficient for binding to MTA2 and HDAC1. However, a significant reduction of the recovery of MTA2 and HDAC1 was observed in an experiment using ⌬C174 compared with that in experiments using mutants with shorter C-terminal deletions (such as ⌬C221). Therefore, it was suggested that there might be a region facilitating MTA2-and HDAC1-MBD3 association in amino acids 174 -220. We also examined whether MBD3 H30K/F34Y, a proficient type of the protein in methyl-CpG binding, associates with MTA2 and HDAC1 or not (Fig. 6D) . The results showed that this mutant protein interacts with MTA2 and HDAC1 as efficiently as the wild type MBD3.
DISCUSSION
In this study, we demonstrated that human MBD3 has no appreciable mCpG-specific DNA-binding activity. The lack of DNA-binding activity in MBD3 appears to be due to two reasons. First, the amino acid substitution of the well conserved Lys-30 and Tyr-34 in MBD3 is the major reason why MBD3 lost its mCpG-specific DNA-binding activity. This was proven by the fact that simultaneous corrections of these amino acids to the conserved residues resulted in conferring significant mCpG-binding activity to MBD3. Second, the presence of Phe at residue 34 positively inhibits the potential DNA-binding activity of MBD3 because the F34A mutant showed significant DNA-binding activity, albeit nonspecific to methyl or nonmethyl CpG. One potential explanation for the lack of any DNA-binding activity in the presence of Phe at residue 34 is that this bulky amino acid may significantly change the structural framework of the protein. However, given that MBD2b Y34F and MBD2b K30H/Y34F bind to DNA nonspecifically (Fig. 3, D and E) , the effect of Phe at residue 34 appears to be context-dependent. Collectively, the presence of Tyr at residue 34 (and equivalent positions) in conventional MBDs is important for conferring mCpG specificity, a biochemical result consistent with that of the structural study (16) . Another unexpected finding is that even if the H30K/F34Y MBD3 mutant protein showed significant mCpG-binding activity in vitro, when expressed in vivo it did not associate with the mCpG-rich pericentromeric regions in NIH 3T3 cells. This observation led us to suggest that the in vitro binding activity of the MBD proteins does not directly lead to the association of the proteins with the mCpG-rich regions in vivo.
Functions of MBD in MBD3-MBD2b and MBD3 are highly homologous (71% identity), and MBD2 and MBD3 genes have very similar genome structures although mapped to different chromosomes in mouse and human (20) . Therefore, it was suggested that these genes have diverged from a relatively recent common ancestor (20) . Why then did MBD3 lose its DNA-binding activity during evolution, and does it function as a core component of the NuRD/Mi2 complex while maintaining MBD? In this study, we demonstrated that MBD3 MBD is necessary and sufficient for the physical interaction with MTA2 and HDAC1. We believe that this secondary role played by MBD is the reason why MBD3 has evolutionarily conserved the apparently "useless" MBD. The dual roles of MBD, namely binding to mCpG and interacting with NuRD/Mi2 components, are not exclusive of each other because we have noted that the MBD3 H30K/F34Y mutant protein associates with MTA2 or HDAC1 (Fig. 6D) and that MBD2b MBD also interacts with MTA2 and HDAC1 in vitro. 2 However, we do not know whether one MBD molecule simultaneously interacts with mCpG and proteins or not. The substitutions at Lys-30 and Tyr-34 to His-30 and Phe-34, respectively, should have specified the role of MBD3 as a protein-interacting protein rather than as a DNA-binding protein. Previously (15), we have shown that MBD2 and MBD3 form a heterodimer via an interaction between the coiled-coil domains of the two proteins. Therefore, it can be imagined that the ancestor of MBD2/MBD3 forms a similar dimer that has two mCpG-interacting domains in one complex. During the course of evolution, MBD3 MBD lost its mCpG-binding activity and became specialized as an adaptor protein for MTA2 and HDAC1. The current MBD2-MBD3 heterodimer has a single mCpG-interacting domain provided by MBD2 and two potential MTA2/HDAC1-interacting domains provided by MBD2 and MBD3. However, it is possible that the ability of MBD2 to bind to MTA2 or HDAC1 is not functional in vivo because the same region binds to mCpG.
There are other examples of domain structures that are evolutionarily conserved while losing their original function. PAF400, a component of the PCAF complex, has a typical domain characterizing the ATM family (21) . However, the PAF400 ATM kinase-like domain has mutations at amino acid residues responsible for the kinase activity, and indeed, no catalytic activity was demonstrated with PAF400. As proposed for MBD3 in this study, a second important role may be achieved by the catalytically inactive ATM domain of PAF400.
Independence of the in Vitro mCpG-Binding Activity from the in Vivo mCpG-Rich Heterochromatin-associating Activity in MBD Proteins-One unexpected observation was that the H30K/F34Y MBD3 mutant did not associate with the mCpGrich pericentromeric regions in NIH 3T3 cells. Two possibilities can be envisioned. First, it is possible that the MeCP2, MBD1, MBD2, and MBD4 proteins, which show proficient pericentromeric association in vivo, may have a second domain in addition to MBD that facilitates the localization of proteins at specific regions in vivo. MBD3 may not have this second domain. There have been precedent studies suggesting this possibility. It was reported that when a MeCP2 mutant protein that had a deletion in MBD was overexpressed, a small fraction of the protein still associated with the pericentromeric regions. This result suggested the presence of a second domain in MeCP2 that MBD-independently facilitated the localization of MeCP2 at the pericentromeric regions (22) . In another study, it was found that GFP-MBD1 localization at the pericentromeric regions did not change markedly in DNMT1 Ϫ/Ϫ ES cells that contained a very low level of mCpG (2) . This finding suggested that the localization of MBD1 at the pericentromeric regions might be partly mCpG-independent.
The second possibility is that MBD3 may have an additional domain that facilitates the recruitment of the protein to the NuRD⅐Mi2 complex, and this domain is not present in other MBD proteins. Recently, the zinc-finger protein called p66 was identified as a component of the MeCP1 complex. p66 also binds to MBD3, but not to MBD2, and possibly determines the intra-nuclear localization of MBD3 (23) . p66 or its related proteins may be a candidate for the factor that positively influences the localization of MBD3 in the NuRD⅐Mi2 complex and outside the pericentromeric regions.
Interestingly, MBD2b MBD Y34F accumulated at the pericentromeric regions although it had no mCpG-specific DNAbinding activity. This result suggests that the mCpG-specific DNA-binding activity is largely dispensable for the pericentromeric localization of MBD proteins and supports the notion that a second determinant is required for the correct targeting of the protein in vivo. Because we have not identified any mutant MBD that lacks nonspecific DNA-binding activity but retains the ability to accumulate at the pericentromeric regions, it remains unclear whether the nonspecific DNA-binding activity of MBD proteins is required for the heterochromatin targeting in vivo or not. The second mutation of K30H in MBD2b abolished the pericentromeric accumulation of the protein when it was present simultaneously with Y34F. This observation suggests that a region distinct from MBD but overlapping with Lys-30 may be important to recruit wild type MBD2 to the mCpG-rich regions in vivo, according to the first hypothesis. Although both MBD2b MBD and MBD3 H30K/ F34Y associate with MTA2 and HDAC1 in vitro (discussed above), MBD2b MBD is localized at the pericentromeric regions, whereas MBD3 H30K/F34Y is not. This observation indicates that the interaction of MBD with MTA2 and HDAC1 in vitro is not the determinant of the protein localization in vivo. Therefore, there should be a second domain in MBD3 outside of amino acid 30 or 34 that is recognized by the NuRD/ Mi2 complex, according to the second hypothesis.
In this study, we have expressed and analyzed recombinant proteins containing the MBDs of MBD2b and MBD3 but lacking unique regions such as the glutamate-rich C-terminal tail in MBD3. Therefore, the additional domain unique to MBD2b or MBD3 should reside in the highly conserved MBDs. No noticeable sequence was recognized in the MBD sequences of MBD2b and MBD3, however. Further studies are necessary to determine why the H30K/F34Y MBD3 mutant did not associate with the mCpG-rich region in vivo.
